Prelude Capital Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Prelude Capital Management’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-324,802	Closed	-$12.8M	–	1493
2023 Q2	$12.8M	Buy	324,802 +309,573	+2,033%	+$10.9M	0.83%	10
2023 Q1	$371K	Sell	15,229 -2,068	-12%	-$45.3K	0.02%	571
2022 Q4	$370K	Buy	+17,297	New	+$369K	0.02%	701
2017 Q4	–	Sell	-10,000	Closed	-$28K	–	1810
2017 Q3	$28K	Buy	10,000 +800	+9%	+$2.16K	﹤0.01%	1250
2017 Q2	$24K	Buy	+9,200	New	+$25.1K	﹤0.01%	1219
2016 Q4	–	Sell	-5,460	Closed	-$252K	–	1846
2016 Q3	$252K	Buy	+5,460	New	+$308K	0.03%	496
2015 Q3	–	Sell	-1,200	Closed	-$62K	–	1878
2015 Q2	$62K	Buy	+1,200	New	+$59.7K	0.01%	1077
2014 Q3	–	Sell	-1,860	Closed	-$79K	–	2207
2014 Q2	$79K	Buy	+1,860	New	+$68.2K	0.01%	1200

Prelude Capital Management's ISEE Position: Q3 2023 in Review

Prelude Capital Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 324,802 shares — an estimated $12.8M sold.

Prelude Capital Management first reported a position in ISEE in Q2 2014 and held it in 8 quarters. The position peaked at $12.8M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

Prelude Capital Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Prelude Capital Management sold 324,802 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $12.8M.
Prelude Capital Management first reported a position in IVERIC bio, Inc. Common Stock in Q2 2014 and held it in 8 quarters.
Prelude Capital Management's IVERIC bio, Inc. Common Stock position peaked at $12.8M in Q2 2023.
0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.